^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | VEGF inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
114P - PD-L1 prevalence and association with clinical outcomes among metastatic renal cell carcinoma patients treated with targeted therapies
Published date:
09/14/2020
Excerpt:
Among the 255 aRCC patients, the majority received VEGF inhibitors (mainly sunitinib [44%], pazopanib [38%])…A negative association (p=0.04) was observed with OS, with shorter median survival for PD-L1+ (14.5 months [95%CI 10.2, 18.3]) compared with PD-L1 (28.3 months [95%CI 20.5,35.2]) When excluding patients receiving IO therapy (6%), response and PFS did not change...PD-L1 expression may be a negative prognostic factor among aRCC patients.
